Latest Regulatory Milestones News

Altamin Limited reports steady progress on its Lazio and Gorno projects, with positive testwork confirming the feasibility of sulphate of potash, lithium carbonate, and boron recovery from geothermal brines. The company moves closer to pre-feasibility studies and environmental approvals amid a tight cash position.

AKORA Resources has successfully renewed its main tenement PR10430 for the Bekisopa Iron Ore Project, marking a pivotal step under Madagascar’s updated Mining Code and reinforcing the project’s path to production.

Prospect Resources has declared a maiden JORC-compliant copper resource of 107.2 million tonnes at 0.5% copper at its Mumbezhi Project in Zambia, alongside securing a strategic A$15.2 million investment from First Quantum Minerals. This milestone advances the project towards development with Phase 2 drilling planned for Q2 2025.

Neurizon Therapeutics reported a sharp rise in half-year losses to $7.28 million but marked significant progress with its lead drug NUZ-001 entering a major ALS clinical trial and securing critical regulatory designations.

PYC Therapeutics has launched a A$145.8 million pro-rata accelerated non-renounceable entitlement offer to fund late-stage clinical trials across its pipeline targeting rare diseases with high unmet needs. The capital raise aims to extend the company’s cash runway beyond FY27, supporting four drug candidates through critical human safety and efficacy milestones.

Trigg Minerals has secured NSW Government approval for the transfer of its Achilles Project licence, enabling formal exploration of the high-grade Wild Cattle Creek antimony deposit.

Artrya Limited has launched a A$15 million capital raising to fund the development and commercial rollout of its Salix AI-powered coronary artery disease diagnostic platform, targeting the lucrative US healthcare market.

AVITA Medical reported a strong 30% increase in Q4 2024 commercial revenue and amended its credit agreement with OrbiMed to adjust revenue covenants through 2026. The company is poised for significant growth with new product rollouts and expects profitability by year-end 2025.

AVITA Medical reported a robust 30% increase in Q4 2024 commercial revenue alongside key FDA clearances, setting the stage for ambitious growth in 2025.

Pure Foods Tasmania Limited (ASX: PFT) will recommence trading on the ASX from 14 February 2025 following the lifting of its suspension after submitting reissued financial statements with an unqualified audit opinion.

VHM Limited has unveiled a staged development plan for its Goschen Rare Earths and Mineral Sands Project, targeting first production by late 2026 and a scalable expansion to 5Mtpa by 2029 with robust financial returns.

Cavalier Resources has completed and submitted all necessary mining approvals for the Crawford Gold Project, moving decisively toward production amid strong gold prices and ongoing funding talks.